INTRODUCTION
============

Radical cystectomy with pelvic lymph node dissection (PLND) is currently the gold standard treatment for muscle-invasive bladder cancer and high-risk recurrent bladder cancer \[[@B1]\]. However, the procedure is associated with high perioperative morbidity \[[@B2]\]. Recent technological advancements in the field of minimally invasive surgery have led to novel techniques such as laparoscopic radical cystectomy and robot-assisted radical cystectomy (RARC) in an effort to reduce the high perioperative morbidity associated with open radical cystectomy (ORC) \[[@B3]\]. The potential benefits include decreased estimated blood loss, fewer transfusions, enhanced recovery of bowel function, shorter length of stay, and fewer postoperative complications \[[@B4][@B5]\]. Since the first publication in 2003 describing its use, the application of RARC has gradually increased with increasing evidence revealing its feasibility as an alternative to open surgery in bladder cancer treatment \[[@B6][@B7]\]. In the United States, RARC has gradually increased from 16.7% in 2010 to 25.3% in 2013, while ORC procedures have declined from 73.7% to 60.6% over the same period \[[@B8][@B9]\]. However, complication rates reported for RARC with extracorporeal urinary diversion (ECUD) remain substantial which has lead current trends to move beyond ECUD towards RARC with totally intracorporeal urinary diversion (ICUD) as a means for achieving better postoperative outcomes \[[@B5][@B10][@B11][@B12]\]. Such notions are due to the possibility of reduced gastrointestinal complication rates associated with less bowel manipulation and mobilization during ICUD procedures and limited peritoneal cavity exposure to air \[[@B13]\]. However, major concerns are associated with the transition from ECUD to ICUD because of the steep learning curve and the ambiguity of impact on oncological and functional outcome. The primary endpoint of this study was to evaluate RARC in terms of its transition from ECUD to ICUD and to investigate its oncological and functional outcome.

MATERIALS AND METHODS
=====================

1. Patients and study design
----------------------------

This retrospective study was done according to the Declaration of Helsinki and approved by the Korea University Institutional Review Board (IRB no. 2010AN0168). Informed consent for research was obtained from all patients prior to RARC. From August 2007 to November 2017, 120 bladder cancer patients were treated with RARC either with an ECUD, ICUD, or with a ureterocutaneostomy by a single surgeon at a tertiary referral hospital. All patients had proven invasive or recurrent high-grade urothelial carcinoma by transurethral resection of the bladder tumor. Data was collected from a retrospective database and divided into 3 subgroups in order of the operation date. Patient demographics such as sex, body mass index (BMI), perioperative conditions, and the location and type of urinary diversion were compared. Overall oncological and functional outcomes were derived from the 120 cases of RARC. Additional analyses of the 3 subgroups were performed to evaluate the oncological and functional outcomes across the learning curve.

Postoperative continence rates were investigated for 58 orthotopic neobladder cases with a minimum of 1 year of follow-up. Continence rates for post operation 1, 3, 6, and 12 months derived and checked to see if clean intermittent catheterization (CIC) was needed at any point throughout the follow-up period. Daytime and nighttime continence was defined as the usage of 0 to 1 safety pad.

Postoperative functional outcome for sexual potency was derived from a patient questionnaire survey, the International Index of Erectile Function (IIEF)-5, taken preoperatively and postoperatively at 3, 6, and 12 months. Forty patients with either an orthotopic neobladder substitution (n=23) or ileal conduit (n=17) satisfied a minimum follow-up period of 12 months and completed all questionnaires. These cases were analyzed to evaluate potency preservation. Potency was defined as the ability to maintain rigidity satisfactory for penetration throughout intercourse on more than half of the attempts with or without the aid of phosphodiesterase-5 inhibitors (PDE5-I).

2. Surgical technique
---------------------

All patients underwent RARC with either a standard or an extended pelvic lymphadenectomy ([Fig. 1](#F1){ref-type="fig"}). A classical Studer reservoir was adopted for orthotopic neobladder substitution. The surgical techniques for RARC with PLND from basic patient positioning and port placement to the boundaries of standard and extended pelvic lymphadenectomy have been described previously \[[@B14]\], along with detailed descriptions of the ICUD and neurovascular bundle preservation techniques \[[@B15]\] ([Fig. 2](#F2){ref-type="fig"}).

For radical cystectomies with orthotopic neobladder substitutions in female patients, standard female radical cystectomy with anterior pelvic exenteration was performed with additional round ligament suspension (RLS). The classical technique of anterior pelvic exenteration involving *en bloc* resection of the bladder, urethra, uterus, fallopian tubes, ovaries, and anterior vaginal wall together with lymphadenectomy is described in literature. For RLS, as described by Ali-El-Dein et al. \[[@B16]\], the round ligaments are cut close to the uterus and later anchored to the lateral ends of the vaginal stump for posterior support ([Fig. 3A](#F3){ref-type="fig"}). In carefully selected patients, reproductive organ-sparing radical cystectomy (ROSRC) was performed rather than the classical technique of anterior pelvic exenteration ([Fig. 3B, C](#F3){ref-type="fig"}). Indications for ROSRC were younger age, desire for preservation of sexual function and/or fertility, unifocal tumors, and organ-confined tumors (≤T2b) that had no involvement of the bladder neck, trigone, or bladder base \[[@B17]\].

3. Statistical analysis
-----------------------

Patient demographics, clinical and pathologic variables were analyzed using descriptive statistics. Fisher\'s exact test and chi-square test were used for categorical variables. Survival analysis was performed via Kaplan-Meier statistics and the log-rank test for comparisons. Analysis of covariance (ANCOVA) was used to derive the p-value for continuous variables across the learning curve. PASW Statistics version 18.0 (SPSS Inc., Chicago, IL, USA) was used for statistics, and a p-value \<0.05 was considered significant.

RESULTS
=======

1. Patient demographics
-----------------------

A summary of the patient demographics is presented in [Table 1](#T1){ref-type="table"}. There were no significant differences between the mean age (63.3 years vs. 65.7 years vs. 64.4 years), sex distribution (male: 90.0% vs. 90.0% vs. 75.0%), BMI (24.8 kg/m^2^ vs. 24.7 kg/m^2^ vs. 23.7 kg/m^2^), and perioperative conditions such as history of neoadjuvant chemotherapy (12.5% vs. 17.5% vs. 5.0%) or adjuvant chemotherapy (0.0% vs. 10.0% vs. 20.0%) among the 3 subgroups; cases 1 to 40, 41 to 80, and 81 to 120, respectively ([Table 1](#T1){ref-type="table"}).

However, there was a significant difference in location (intracorporeal vs. extracorporeal) and type of urinary diversion (ileal conduit vs. orthotopic neobladder vs. ureterocutaneostomy). As our series of RARC progressed, the number of ICUDs and orthotopic neobladders increased from an initial 7.5% to 97.5% and 37.5% to 72.5%, respectively.

Overall, ECUD, ICUD, and ureterocutaneostomy were performed in 42, 73, and 5 patients, respectively. Within the ICUD group, 30 (41.1%) and 43 (58.9%) patients each received either an ileal conduit or orthotopic neobladder substitution, while in the ECUD group, 27 (64.3%) and 15 (35.7%) patients each received an ileal conduit and an orthotopic neobladder substitution, respectively.

2. Oncological outcomes
-----------------------

Oncological outcomes are summarized in [Table 2](#T2){ref-type="table"}. Of the 120 patients, 96 patients had a minimum follow-up of one year and were analyzed to determine the overall oncological outcome of RARC. The number of patients in pathologic stage ≤T2, pT3-4, and pTanyN1-3 were 64, 14, and 18, respectively. Also, the number of recurrences for each group were 9 (14.1%, mean time of recurrence at 22.5 months), 1 (7.1%, at 23 months), and 8 patients (44.4%, at 9.5 months), respectively. Tumor recurrences were observed in 18 patients (18.8%) with a mean time to recurrence of 17.8 months in which 14 patients (77.8%) recurred within two years and 16 patients (88.9%) within 3 years.

The extent of lymph node (LN) dissection gradually evolved towards a more challenging extended PLND during the learning curve and consequently, there was a significant increase in total LN yield from 22.6 to 30.0 and eventually to 34.4 every 40 cases (p\<0.05). For each type of LND, there were no significant differences in nodal yields during the learning curve. There was 1 case (0.8%) of positive soft tissue margin in which the final pathology report was pT3aN0.

The overall survival (OS), recurrence-free survival (RFS) and cancer-specific survival (CSS) were 95.3%, 84.4%, 96.3% at 2 years; 89.4%, 81.4%, 93.3% at 3 years; and 86.6%, 78.7%, 93.3% at 5 years, respectively ([Table 3](#T3){ref-type="table"}). The 3-year OS according to pathologic stage is summarized in [Table 4](#T4){ref-type="table"}. OS, RFS, and CSS, for T2 or less, T3/T4, pTanyN1-3 were 92.6%, 88.1%, 94.5% and 85.7%, 88.9%, 100% and 77.9%, 46.0%, and 82.5%, respectively.

There were no statistically significant differences in the two-year OS, RFS, CSS between segments of the learning curve (OS: 97.3% vs. 92.1% vs. 89.9, p\>0.05; RFS: 84.9% vs. 79.5% vs. 81.9%, p\>0.05; CSS: 97.3% vs. 92.1% vs. 94.6%, p\>0.05) ([Table 5](#T5){ref-type="table"}).

Peritoneal carcinomatosis was observed in 2 cases (2.2%); both cases involved ICUD with orthotopic neobladder substitutions. The final pathology results in both cases were associated with high stage (pT3aN1).

3. Functional outcomes (urinary continence)
-------------------------------------------

Functional outcomes for urinary continence are shown in [Table 5](#T5){ref-type="table"}. Among the 120 cases of RARC, orthotopic neobladder substitution was performed in 58 cases comprising 6 female and 52 male patients. Of the 52 male patients, 37 satisfied a minimum follow-up period of 1 year and were analyzed to determine the functional outcome for urinary continence. Daytime and nighttime continence rates at postoperative 1, 3, 6, and 12 months were 32.4%, 62.2%, 67.6%, 75.7%, and 18.9%, 35.1%, 40.5%, and 51.4%, respectively. Daytime continence rate at 1 year that remained incontinent at night was 29.7%.

Continence rates for each consecutive group of 40 cases are summarized in [Table 6](#T6){ref-type="table"}. The daytime continence rates at 1 year for cases 1 to 40, 41 to 80, 81 to 120 were each 73.3%, 76.9%, 77.8% while nighttime continence rates were 46.7%, 46.2%, and 66.7%, respectively. There were no significant differences in daytime and nighttime continence rates between groups. The CIC rate decreased significantly from 33.3% to 15.4% and 0.0% eventually with every 40 cases. All cases of male CIC were due to neovesicourethral anastomotic stricture except for 1 case of dysfunctional voiding.

Basic characteristics and functional results for female orthotopic neobladders are summarized in [Table 7](#T7){ref-type="table"}. Among the 6 female orthotopic neobladder substitutions, 3 underwent a ROSRC while the rest had a classical anterior exenteration with RLS. Daytime and nighttime continence was gained within 1 year in all cases except for 1 case of RLS that showed stress urinary incontinence. One case of dysfunctional voiding requiring CIC occurred in the ROSRC group.

4. Functional outcomes (potency recovery)
-----------------------------------------

Of the 120 RARC patients, 40 male RARC patients with either an orthotopic neobladder substitution or ileal conduit satisfied a minimum follow-up of one year. Indications for neurovascular bundle (NVB) preservation included preoperatively potent men with an IIEF-5 score of \>12, clinical stage T2 or less without involvement of the bladder neck, and absence of neurological and penile diseases. Fifteen patients (34.1%) satisfied these indications. However, 3 of these patients were suspected of advanced stage intra-operatively and were excluded from NVB preservation. Eventually, 12 patients underwent either a bilateral or unilateral NVB preservation (11 bilateral & 1 unilateral). The average preoperative and postoperative IIEF-5 score for these 12 patients were 16.8 and 7.7 at one year. The potency preservation rate was 66.7% (n=8) with or without PDE5-I and 33.3% without PDE5-I (n=4) at 1 year.

DISCUSSION
==========

Acknowledged surrogate markers for oncological control and surgical quality include positive surgical margin (PSM) rates and LN yields. Comparing our results with historical data, Herr et al. \[[@B18]\] proposed optimal overall PSM rate (PSMR) ≤10% with a PSMR ≤15% in patients with T3--T4 bladder tumors, and the minimum number of LNs removed should be 10--14. The Pasadena Consensus Panel proposed that acceptable PSMR be \<7% overall, suggesting rates of \<3% for pT2, \<10% for pT3, and \<25% for pT4 \[[@B19]\]. PSMR reported for ORC in the RAZOR trial and Memorial Sloan Kettering Cancer Center (MSKCC) trial were 4.5% and 5.2%, respectively. The LN yield during LND in RARC reported in a systematic review by Yuh et al. \[[@B20]\] was 19 (range: 3--55), with half being an extended LND (yield range: 11--55). In our series, the PSMR was 0.8% overall and 5.6% for stage pT3N0. There were no PSMs in the pT2 or pTanyN1-3 groups. The mean total LN yield was 29.0. Therefore, the results of surrogate markers for our 120 cases of RARC are in line with historical data for ORC and currently available RARC results. In addition, these oncological surrogate markers are well established from the beginning and are maintained throughout the learning curve.

Long-term cancer-related deaths and RFS rates are the primary measurement of treatment efficacy in radical cystectomy. Due to lack of long-term follow-up in our study, comparisons were made based on large historical retrospective ORC series. A long-term analysis of survival in 1,000 ORC patients by Hautmann et al. \[[@B21]\] reported a five-year OS of 65.5%. According to a systematic review of RARC outcome, 5-year and 3-year estimates for OS, RFS, and CSS were 39% to 66%, 53% to 74%, 66% to 80% and 61% to 80%, 67% to 76%, 68% to 83%, respectively \[[@B20]\]. According to the RAZOR trial, the 2-year RFS for RARC and ORC was 72.3% vs. 71.6% and the 2-year OS 80.2% vs. 79.1%, respectively \[[@B5][@B10][@B11][@B12]\]. The intermediate term OS, RFS, and CSS of this study seemed to present a comparable result to the ORC series and to currently available RARC results. Analysis of the learning curve indicated that the 2-year OS, RFS, CSS for cases 1 to 40, 41 to 80, 81 to 120 were 97.3%, 84.9%, 97.3% and 92.1%, 79.5%, 92.1% and 89.9%, 81.9%, 94.6%, respectively. The oncological outcome was maintained throughout the learning curve and the transition from ECUD to ICUD could be safely achieved without compromising the oncological outcome.

There were no significant differences in continence rates for male RARC throughout the learning curve. Previous publications have reported daytime continence rates to be 85%--100% and nighttime continence rates to be 60% to 95% for ORC \[[@B22][@B23]\]. However, other reports have indicated a wide array of continence rates from as low as 18% to as high as 92% at 1-year \[[@B24][@B25]\]. The variability is caused by the vast array of differences in the definition of continence, making comparison of continence rates difficult. Sharing our definition of continence as usage of 0 to 1 safety pad, a recent publication of male ORC showed daytime continence rates at 3, 6, and 12 months to be 34%, 47%, and 71%, and nighttime continence rates to be 14%, 25%, and 37%, respectively \[[@B26]\]. The reported daytime continence rates for RARC with orthotopic neobladder substitution ranged from 73.3% to 88.0% during the daytime and 55.5% to 58.1% at nighttime \[[@B27][@B28]\] In our study, daytime and nighttime continence rates at postoperative 1, 3, 6, and 12 months were each 32.4%, 62.2%, 67.6%, 75.7%, and 18.9%, 35.1%, 40.5%, 51.4%, respectively. An early daytime continence gain of 32.4% at 1 month was noticeable. A postoperative 1-year pad-free daytime continence rate of 75.7% and 1-year pad-free nighttime continence rate of 51.4% were achieved. Despite the limited data for comparison, these results are in accordance with historical ORC and contemporary RARC literature. The daytime and nighttime continence rates during the learning curve at one year for cases 1 to 40, 41 to 80, 81 to 120 were 73.3%, 76.9%, 77.8% and 46.7%, 46.2%, 66.7%, respectively. There were no significant differences in daytime and nighttime continence rates, implying that satisfactory continence rates are achieved early on in the learning curve and maintained throughout the transition to ICUD.

The majority of cases in which CIC was required wereassociated with neovesicourethral anastomotic stricture. Seven of 52 (13.5%) male RARC patients with orthotopic neobladder substitutions required CIC. Six of the seven (85.7%) CIC cases were related to neovesicourethral anastomotic stricture while the other was due to dysfunctional voiding. Five of six (83.3%) neovesicourethral anastomotic strictures belonged to the initial 40 cases. These were all ECUD cases and required an additional surgical intervention of internal urethrotomy for the anastomotic stricture. The remaining one case of neovesicourethral anastomotic stricture was an ICUD and belonged to the 41 to 80 group which did not require surgical intervention but only periodic dilatation. In our experience, it seems as though neovesicourethral anastomotic stricture rates are higher in ECUD cases, possibly due to tensions created by gravity during a steep Trendelenburg position. Therefore, neovesicourethral anastomotic stricture may be prevented by minimizing tension during neovesicourethral anastomosis, resulting in a watertight seal with better blood supply and wound healing.

Potency recovery at one-year has been reported to range from 41% to 63% \[[@B29][@B30]\]. In our series of RARC, the potency recovery rate at one year was 66.7%. These results are comparable to currently available results. Future prospective data collection and analysis to better evaluate the functional outcome is required.

Incontinence and hypercontinence rates following classical radical cystectomy with orthotopic neobladder substitutions have been reported to range from 34% to 44% and 35% to 61%, respectively \[[@B17]\]. Hypercontinence has been described to be the result of downward and posterior migration of the neobladder during straining. Surgical modifications towards reducing chronic urinary retention rates include suspending the angles of the closed vaginal stump \[[@B16]\]. In our series of female RARC, those not indicated for ROSRC underwent anterior exenteration with RLS. There were no cases of hypercontinence needing permanent CIC. Our data suggest that anterior superior fixation with RLS is advantageous in terms of preventing hypercontinence.

Potential limitations to this study include its retrospective, single-institution, nonrandomized study design with the possibility of selection bias for patients with lower tumor burden the early stages of RARC. Moreover, the short clinical and oncological follow-up period remain as potential limitations. Also, rather than a direct comparative analysis between ORC and RARC, we used historical ORC data as reference for comparison with RARC. Nevertheless, this study holds meaning in that both oncological and functional data for RARC are reported while current literature remain immature.

CONCLUSIONS
===========

RARC results in comparable functional and oncological outcomes as in historical ORC series. Therefore, when oncological principals regarding ORC are followed, RARC can be an appropriate minimally invasive surgical option for patients with invasive bladder cancer. In addition, the oncological and functional outcomes are well maintained throughout the learning curve. Furthermore, the transition from ECUD to ICUD may be successfully achieved without compromising oncological and functional outcomes.
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![Neurovascular bundle preservation. (A) Intrafascial dissection of the neurovascular bundle from the lateral prostatic surface, left side. (B) The final aspect.](icu-60-463-g002){#F2}

![Female robot-assisted radical cystectomy. (A) Round ligament suspension. (B) Reproductive organ-sparing radical cystectomy. (C) The final aspect. RL, round ligament; FT, fallopian tube; UC, urethral catheter.](icu-60-463-g003){#F3}

###### Demographics and characteristics of 120 robot-assisted radical cystectomy cases, overall and by patient series in chronological order of receipt of surgery

![](icu-60-463-i001)

  Characteristic              Case series                                         
  --------------------------- ------------- ------------ ----------- ------------ ----------
  Number of patients          40            40           40          120          
  Age (y)                     63.3±9.8      65.7±11.2    64.4±11.6   64.5±11.0    0.628^a^
  Sex                                                                             0.095^b^
   Male                       36 (90.0)     36 (90.0)    30 (75.0)   102 (85.0)   
   Female                     4 (10.0)      4 (10.0)     10 (25.0)   18 (15.0)    
  Body mass index (kg/m^2^)   24.8±2.9      24.7±3.0     23.7±3.6    24.4±3.2     0.325^a^
  Perioperative condition                                                         
   Neoadjuvant chemotherapy   5 (12.5)      7 (17.5)     2 (5.0)     14 (11.7)    0.215^c^
   Adjuvant chemotherapy      0 (0.0)       4 (10.0)     8 (20.0)    12 (10.0)    0.050^c^
  ECUD cases                  34 (85.0)     7 (17.5)     1 (2.5)     42 (35.0)    0.000^c^
  ICUD cases                  3 (7.5)       31 (77.5)    39 (97.5)   73 (60.8)    0.000^c^
  Other                       3 (7.5)^d^    2 (5.0)^d^   0 (0.0)     5 (4.2)      
  Type of urinary diversion                                                       0.004^c^
   Ileal conduit              22 (55.0)     24 (60.0)    11 (27.5)   57 (47.5)    
   Orthotopic neobladder      15 (37.5)     14 (35.0)    29 (72.5)   58 (48.3)    
   Ureterocutaneostomy        3 (7.5)       2 (5.0)      0 (0.0)     5 (4.2)      

Values are presented as number only, mean±standard deviation, or number (%).

ECUD, extracorporeal urinary diversion; ICUD, intracorporeal urinary diversion.

^a^:Analysis of covariance, ^b^:chi-square test, ^c^:Fisher\'s exact test, ^d^:other refers to ureterocutaneostomy.

###### Oncological outcomes, overall and by patient series in chronological order of receipt of surgery
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  Oncological result       1--40       41--80      81--120      Total (n=120)   p-value
  ------------------------ ----------- ----------- ------------ --------------- ----------
  Pathologic T stage, N0                                                        0.301^a^
   T2 or less              30 (75.0)   26 (65.0)   20 (50.0)    76 (63.3)       
   T3 or T4                6 (15.0)    4 (10.0)    8 (20.0)     18 (15.0)       
  LN positive              4 (10.0)    10 (25.0)   12 (30.0)    26 (21.7)       0.525^a^
   T any, N1               1 (2.5)     5 (12.5)    5 (12.5)     11 (9.2)        
   T any, N2               3 (7.5)     4 (10.0)    4 (10.0)     11 (9.2)        
   T any, N3               0 (0.0)     1 (2.5)     3 (7.5)      4 (3.3)         
  Positive margin          0 (0.0)     0 (0.0)     1 (2.5)^b^   1 (0.8)^b^      
  Type of LND                                                                   0.002^a^
   Standard                17 (42.5)   4 (10.0)    7 (17.5)     28 (23.3)       
   Extended                23 (57.5)   36 (90.0)   33 (82.5)    92 (76.7)       
  LN yield                 22.6±13.0   30.0±13.2   34.4±18.0    29.0±15.6       0.002^c^
   Standard                12.5±6.7    19.8±8.5    20.0±9.4     15.4±8.2        0.060^c^
   Extended                30.1±11.5   31.2±13.2   37.9±18.0    33.1±14.9       0.115^c^

Values are presented as number (%) or mean±standard deviation.

LN, lymph node; LND, lymph node dissection.

^a^:Chi-square test, ^b^:the final pathology report for the margin positive case was pT3aN0, ^c^:analysis of covariance.

###### The two-year, three-year, and five-year survival outcomes in 96 patients with a minimum 1-year follow-up period
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  Overall survival outcomes   OS (%)   RFS (%)   CSS (%)
  --------------------------- -------- --------- ---------
  2 years                     95.3     84.4      96.3
  3 years                     89.4     81.4      93.3
  5 years                     86.6     78.7      93.3

OS, overall survival; RFS, recurrence-free survival; CSS, cancer-specific survival.

###### The 3-year OS, RFS, CSS in 96 patients with minimum 1-year follow-up according to pathology stage (median follow-up period of 47.1 months)
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  Final pathology stage                     OS (%)   RFS (%)   CSS(%)
  ----------------------------------------- -------- --------- --------
  T2 or Less, N0 (n=64) (T0/Tis/Ta/T1/T2)   92.6     88.1      94.5
  T3/T4, N0 (n=14)                          85.7     88.9      100
  T any, N 1, 2, 3 (n=18)                   77.9     46.0      82.5

OS, overall survival; RFS, recurrence-free survival; CSS, cancer-specific survival.

###### The 2-year OS, RFS, CSS, overall and by patient series in chronological order of receipt of surgery
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  2-year   1--40 (%)   41--80 (%)   81--120 (%)   Total (n=120)
  -------- ----------- ------------ ------------- ---------------
  OS       97.3        92.1         89.9          95.3
  RFS      84.9        79.5         81.9          84.4
  CSS      97.3        92.1         94.6          96.3

OS, overall survival; RFS, recurrence-free survival; CSS, cancer-specific survival.

###### Functional outcomes (urinary incontinence) in male patients (n=37), overall and in patient series according to chronological order of receipt of surgery
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                                                    1--40       41--80      81--120    Total (n=120)   p-value
  ------------------------------------------------- ----------- ----------- ---------- --------------- ----------
  Neobladder (no. of cases)                         15          13          9          37              
  Daytime continence                                                                                   
   At 1 month                                       5 (33.3)    3 (23.1)    4 (44.4)   12 (32.4)       0.164^a^
   At 3 months                                      8 (53.3)    9 (69.2)    6 (66.7)   23 (62.2)       0.653^a^
   At 6 months                                      8 (53.3)    10 (76.9)   7 (77.8)   25 (67.6)       0.431^a^
   At 12 months                                     11 (73.3)   10 (76.9)   7 (77.8)   28 (75.7)       0.211^a^
  Nighttime continence                                                                                 
   At 1 month                                       2 (13.3)    2 (15.4)    3 (33.3)   7 (18.9)        0.111^a^
   At 3 months                                      4 (26.7)    4 (30.8)    5 (55.6)   13 (35.1)       0.373^a^
   At 6 months                                      5 (33.3)    5 (38.5)    5 (55.6)   15 (40.5)       0.631^b^
   At 12 months                                     7 (46.7)    6 (46.2)    6 (66.7)   19 (51.4)       0.644^a^
  Clean intermittent catheterization rate           5 (33.3)    2 (15.4)    0 (0.0)    7 (18.9)        0.038^a^
  Vesico-urethral anastomosis site stricture rate   5 (33.3)    1 (7.7)     0 (0.0)    6 (16.2)        0.031^a^

Values are presented as number only or number (%).

^a^:Fisher\'s exact test, ^b^:chi-square test.

###### Functional outcome (urinary incontinence) in female patients (n=6)
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              Age   BMI (kg/m^2^)   Stage    Daytime continence gain (POD)   Nighttime continence gain (POD)   Chronic retention (CIC)
  ----------- ----- --------------- -------- ------------------------------- --------------------------------- -------------------------
  1 (ROSRC)   55    20.6            pT3aN0   6 months                        6 months                          X
  2 (ROSRC)   70    29.9            pTisN0   2 months                        2 months                          △
  3 (RLS)     55    21.3            pT3aN1   Incontinence at 6 months        Incontinence at 6 months          X
  4 (RLS)     61    22.1            pT1N1    12 months                       12 months                         X
  5 (RLS)     57    18.3            pT1N0    12 months                       Incontinence at 1 year            X
  6 (ROSRC)   58    25.2            pT1N0    6 months                        6 months                          X

BMI, body mass index; POD, post-operative days; CIC, clean intermittent catheterization; ROSRC, reproductive organ-sparing radical cystectomy;

RLS, anterior exenteration and round ligament suspension; Δ, combined voiding (voiding with partial CIC aid).
